Photo by nci from unsplash
Significance Resistance to targeted and immunotherapeutic agents has emerged as a critical impediment to melanoma therapy. This study identifies the bromosporine/cobimetinib combination as a therapeutic strategy with broad-based activity in… Click to show full abstract
Significance Resistance to targeted and immunotherapeutic agents has emerged as a critical impediment to melanoma therapy. This study identifies the bromosporine/cobimetinib combination as a therapeutic strategy with broad-based activity in multiple settings, including in both treatment-naive and resistant BRAF-mutant melanoma and in NRAS- and NF-1-mutant melanoma following resistance to PD-1 blockade.
Keywords:
bromodomain inhibition;
melanoma;
inhibition overcomes;
resistance;
overcomes treatment
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!